Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Papillomavirus vaccines in perspective.

Kahn JA, Burk RD.

Lancet. 2007 Jun 30;369(9580):2135-7. No abstract available.

PMID:
17602733
2.

Cell-mediated immune response: a clinical review of the therapeutic potential of human papillomavirus vaccination.

Meyer SI, Fuglsang K, Blaakaer J.

Acta Obstet Gynecol Scand. 2014 Dec;93(12):1209-18. doi: 10.1111/aogs.12480. Epub 2014 Sep 20. Review.

PMID:
25146484
3.

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.

Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, Harper DM, Hedrick JA, Jaisamrarn U, Limson GA, Dionne M, Quint W, Spiessens B, Peeters P, Struyf F, Wieting SL, Lehtinen MO, Dubin G; HPV PATRICIA study group.

Lancet. 2007 Jun 30;369(9580):2161-70. Erratum in: Lancet. 2007 Oct 20;370(9596):1414.

PMID:
17602732
5.

Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.

Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Lupinacci LC, Giacoletti KE, Sings HL, James MK, Hesley TM, Barr E, Haupt RM.

J Natl Cancer Inst. 2010 Mar 3;102(5):325-39. doi: 10.1093/jnci/djp534. Epub 2010 Feb 5.

6.

[HPV vaccination and cervical cancer screening].

Sigurdsson K.

Laeknabladid. 2007 Dec;93(12):819, 821. Icelandic. No abstract available.

PMID:
18057470
7.

Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years.

Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Perona P, Poncelet S, Zahaf T, Hardt K, Descamps D, Dubin G; HPV Study Group for Adult Women.

Vaccine. 2009 Jan 22;27(4):581-7. doi: 10.1016/j.vaccine.2008.10.088. Epub 2008 Nov 18.

PMID:
19022320
8.

A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.

Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Dillner J, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Maansson R, Lu S, Vuocolo S, Hesley TM, Saah A, Barr E, Haupt RM.

Cancer Prev Res (Phila). 2009 Oct;2(10):868-78. doi: 10.1158/1940-6207.CAPR-09-0031. Epub 2009 Sep 29.

9.

Human papillomavirus vaccine efficacy: aligning expectations with reality.

Smith-McCune KK.

Gynecol Oncol. 2008 Oct;111(1):1-2. doi: 10.1016/j.ygyno.2008.09.001. No abstract available.

PMID:
18922296
10.

Human papillomavirus vaccines versus cervical cancer screening.

Stanley M.

Clin Oncol (R Coll Radiol). 2008 Aug;20(6):388-94. doi: 10.1016/j.clon.2008.04.006. Epub 2008 Jun 5. Review.

PMID:
18538554
11.

Human papillomavirus vaccination--reasons for caution.

Haug CJ.

N Engl J Med. 2008 Aug 21;359(8):861-2. doi: 10.1056/NEJMe0804638. No abstract available.

13.

Gynaecological cancer: HPV vaccine: is age just a number?

Stone L.

Nat Rev Urol. 2014 Nov;11(11):605. doi: 10.1038/nrurol.2014.268. Epub 2014 Sep 23. No abstract available.

PMID:
25245243
14.

How many CIN2+ lesions can be avoided through HPV 16/18 vaccination?

Hulstaert F, De Laet C.

Acta Obstet Gynecol Scand. 2009;88(7):859; author reply 859-60. doi: 10.1080/00016340902989005. No abstract available.

PMID:
19449218
15.

[Vaccine against human papillomavirus : PATRICIA Study (PApilloma TRIal against Cancer In young Adults)].

Kaufmann AM, Nitschmann S.

Internist (Berl). 2010 Mar;51(3):410, 412-3. doi: 10.1007/s00108-009-2575-8. German. No abstract available.

PMID:
20127302
16.

Cervical cancer vaccine development.

Frazer IH.

Sex Health. 2010 Sep;7(3):230-4. doi: 10.1071/SH09132. Review.

PMID:
20719210
17.

No evidence in US of HPV16/18 cancer precursor reduction.

Pendleton ME, Ruffin MT 4th, Harper DM.

Vaccine. 2016 Jan 4;34(2):200. doi: 10.1016/j.vaccine.2015.07.047. Epub 2015 Jul 29. No abstract available.

PMID:
26232544
18.

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine.

Di Mario S, Basevi V, Borsari S, Balduzzi S, Magrini N.

Lancet Oncol. 2012 Feb;13(2):e50; author reply e50. doi: 10.1016/S1470-2045(12)70054-2. No abstract available.

PMID:
22300857
19.

Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.

Rambout L, Hopkins L, Hutton B, Fergusson D.

CMAJ. 2007 Aug 28;177(5):469-79. Epub 2007 Aug 1. Review.

20.

HPV vaccine efficacy in preventing persistent cervical HPV infection: a systematic review and meta-analysis.

La Torre G, de Waure C, Chiaradia G, Mannocci A, Ricciardi W.

Vaccine. 2007 Dec 5;25(50):8352-8. Epub 2007 Sep 29. Review.

PMID:
17996990
Items per page

Supplemental Content

Write to the Help Desk